Genmab (GMAB) said Wednesday it is partnering with artificial intelligence company Anthropic to use AI tools in its research and clinical development operations.
Financial terms were not provided.
The Danish biotechnology company said the agreement will involve building customized AI systems using Anthropic's Claude technology to support activities such as data handling, analysis and preparation of clinical documents, with human oversight in place.
Genmab also said the tools are expected to support clinical development work and complement ongoing investments in digital infrastructure as it advances late-stage antibody programs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments